Bevacizumab in combination with fluoropyrimidine-irinotecan-or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer

Expert Review of Anticancer Therapy

Volumn 15, Issue 11, 2015, Pages 1267-1281

  Grapsa, Dimitra ^a   Syrigos, Konstantinos ^a   Saif, Muhammad Wasif ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

5 fluoouracil (5 FU) leucovorin (LV); Bevacizumab; colorectal cancer (CRC); irinotecan; oxaliplatin; vascular endothelial growth factor (VEGF)

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX; VASCULOTROPIN A;

ARTERY THROMBOSIS; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CAUSE OF DEATH; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; LUNG HEMORRHAGE; MAINTENANCE CHEMOTHERAPY; METASTASIS; METASTATIC COLORECTAL CANCER; NEUROTOXICITY; NEUTROPENIA; PROTEINURIA; SEPSIS; THROMBOSIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84948071094     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1102063     Document Type: Article

References (96)

1. Torre LA, Bray F, Siegel RL., et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108.
2. Edwards BK, Ward E, Kohler BA., et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010; 116: 544-573.
3. Bosetti C, Levi F, Rosato V., et al. Recent trends in colorectal cancer mortality in Europe. Int J Cancer. 2011; 129: 180-191.
4. Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. Mayo Clin Proc. 2007; 82: 114-129.
5. Scheithauer W, Rosen H, Kornek GV., et al. Randomised comparison of combination chemotherapy plus supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993; 306: 752-755.
6. Bekaii-Saab T, Wu C. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2014; 91: 9-34.
7. Jackson AL, Zhou B, Kim WY. HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets. 2010; 14: 1047-1057.
8. Edelman MJ, Hodgson L, Wang X., et al. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer. Cancer and Leukemia Group B 150304. J Thorac Oncol. 2011; 6: 1902-1906.
9. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995; 333: 1757-1763.
10. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer. 1997; 80: 1529-1537.
11. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002; 9: 36-44.
12. Folkman J. What is the evidence that tumors are angiogenesis dependent J Natl Cancer Inst. 1990; 82: 4-6.
13. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987; 235: 442-447.
14. Choi JH, Kim HC, Hy L., et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leucocyte counts. Lung Cancer. 2001; 33: 171-179.
15. Dvorak HF, Brown LF, Detmar M., et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995; 146: 1029-1039.
16. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995; 108: 2369-2379.
17. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23: 1011-1027.
18. Nagy JA, Vasile E, Feng D., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogensis as well as angiogenesis. J Exp Med. 2002; 196: 1497-1506.
19. Li J, Saif MW. Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics. 2009;3: 429-441.
20. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999; 5: 1359-1364.
21. Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm. 2004; 61: S21-26.
22. Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy. 2008; 23S-30S.
23. Kim KJ, Li B, Houck K., et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992; 7: 53-64.
24. Grothey A, Van Cutsem E, Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381: 303-312.
25. Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006; 33: S1-7.
26. Iqbal S, Lenz HJ. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol. 2004; 54: S32-39.
27. Von Baumgarten L, Brucker D, Tirniceru A., et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res. 2011; 17: 6192-6205.
28. Welch S, Spithoff K, Rumble RB., et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010; 21: 1152-1162.
29. Mohile SG, Hardt M, Tew W., et al. Toxicity of bevacizumab in combination with chemotherapy in older patients. Oncologist. 2013; 18: 408-414.
30. Hurwitz H, Fehrenbacher L, Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
31. Fuchs CS, Marshall J, Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007; 25: 4779-4786.
32. Fuchs CS, Marschall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008; 26: 689-690.
33. Sobrero A, Ackland S, Clarke S., et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 2009; 77: 113-119.
34. Heinemann V, Von Weikersthal LF, Decker T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial. Lancet Oncol. 2014; 15: 1067-1075.
35. Saltz LB, Clarke S, Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26: 2013-2019.
36. Hochster HS, Hart LL, Ramanathan RK., et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008; 26: 3523-3529.
37. Schmoll HJ, Cunningham D, Sobrero A., et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol. 2012; 30: 3588-3595.
38. Hochster HS, Grothey A, Shpilsky A. et al. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial. Gastrointestinal Cancers Symp. 2008;23: Abstract 280.
39. Stintzing S, Fischer Von Weikersthal F, Decker T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS mutated tumours in the randomized German AIO study KRK-0306. Ann Oncol. 2012; 23: 1693-1699.
40. Schwartzberg LS, Rivera F, Karthaus M., et al. PEAK: a randomized multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014; 32: 2240-2247.
41. Venook AP, Niedzwiecki D, Lenz HJ., et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetixumab (CET) for patients with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Proc Am Soc Clin Oncol. 2014; 32: LBA3 (abstr).
42. Masi G, Loupakis F, Salvatore L., et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010; 11: 845-852.
43. Loupakis F, Cremolinr C, Masi G., et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014; 371: 1609-1618.
44. Gruenberger T, Bridgewater J, Chau I., et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomized phase II trial. Ann Oncol. 2015; 26: 702-708.
45. Diaz-Rubio E, Gomez-Espana A, Massuti B., et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012; 17: 25-35.
46. Rosati G, Avallone A, Aprile G., et al. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol. 2013; 71: 257-264.
47. Johnsson A, Hagman H, Frodin JE., et al. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT trial. Ann Oncol. 2013; 24: 2335-2341.
48. Koeberle D, Betticher DC, Von Moos R., et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol. 2015; 26: 709-714.
49. Simkens LH, Van Tinteren H, May A., et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomized controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015; 385: 1843-1852.
50. Hegewisch-Becker S, Graeven U, Lerchenmuller CA., et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomized, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015. DOI: 10.1016/S1470-2045(15)00042-X. [Epub ahead of print].
51. Heidelberger C, Chaudhuri NK, Danneberg P., et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature. 1957; 179: 663-666.
52. Ullman B, Lee M, Martin DW Jr., et al., Cytotoxicity of 5-fluoro-2-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci USA. 1978; 75: 980-983.
53. Keyomarsi K, Moran RG. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res. 1986; 46: 5229-5235.
54. Radparvar S, Houghton PJ, Houghton JA. Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol. 1989; 38: 335-342.
55. Park JG, Collins JM, Gazdar AF., et al. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst. 1988; 80: 1560-1564.
56. Machover D, Schwarzenberg L, Goldschmidt E., et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep. 1982; 66: 1803-1807.
57. Madajewicz S, Petrelli N, Rustum YM., et al. Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res. 1984; 44: 4667-4669.
58. Petrelli N, Douglass HO Jr, Herrera L., et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol. 1989; 7: 1419-1426.
59. Petrelli N, Herrera L, Rustum Y., et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol. 1987; 5: 1559-1565.
60. Thirion P, Michiels S, Pignon JP., et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004; 22: 3766-3775.
61. Gustavvson B, Carlsson G, Machover D., et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015; 14: 1-10.
62. Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist. 2005; 10 (Suppl 3): 40-48.
63. Twelves C, Xeloda Colorectal Cancer Group. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer. 2002; 38 (Suppl 2): 15-20.
64. Cassidy J, Twelves C, Van Cutsem E., et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002; 13; 566-575.
65. Diaz-Rubio E, Sastre J, Zaniboni A., et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol. 1998; 9: 105-108.
66. Becouarn Y, Ychou M, Ducreux M., et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol. 1998; 16: 2739-2744.
67. Rougier P, Bugat R, Douillard JY., et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997; 1: 251-260.
68. Firvida JL, Irigoyen A, Vazquez-Estevez S., et al. Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer. 2001; 91: 704-711.
69. Zori Comba A, Blajman C, Richardet E., et al. A randomized phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer. 2001; 37: 1006-1013.
70. Ravaioli A, Marangolo M, Pasquini E., et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol. 2002; 20: 2545-2550.
71. Levi F, Zidani R, Brienza S., et al. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer. 1999; 85: 2532-2540.
72. Bertheault-Cvitkovic F, Jami A, Ithzaki M., et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 1996; 14: 2950-2958.
73. Maiello E, Gebbia V, Guiliani F., et al. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomized phase II study of the Southern Italy Oncology Group. Ann Oncol. 2000; 11: 1045-1051.
74. Douillard JY, Cunningham D, Roth AD., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as fist-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet. 2000; 355: 1041-1047.
75. Saltz B, Cox JV, Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343: 905-914.
76. De Gramont A, Figer A, Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 2938-2947.
77. Goldberg RM, Sargent DJ, Morton RF., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22: 23-30.
78. Aranda E, Diaz-Rubio E, Cervantes A., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol. 1998; 9: 727-731.
79. De Gramont A, Bosset JF, Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997; 15: 808-815.
80. Falcone A, Masi G, Allegrini G., et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol. 2002; 20: 4006-4014.
81. Masi G, Allegrini G, Cupini S., et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol. 2004; 15: 1766-1772.
82. Souglakos J, Androulakis N, Syrigos K., et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a mutlicentre randomized phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006; 94: 798-805.
83. Falcone A, Ricci S, Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007; 25: 1670-1676.
84. Petrelli F, Borgonovo K, Cabiddu M., et al. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer. 2013; 12: 145-151.
85. Bendell JC, Bekaii-Saab TS, Cohn AL., et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012; 17: 1486-1495.
86. Kozloff M, Ulcickas M, Berlin J., et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRITE observational cohort study. Oncologist. 2009; 14: 862-870.
87. Van Cutsem E, Rivera F, Berry S., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009; 20: 1842-1847.
88. Stein A, Glockzin G, Wienke A., et al. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer. 2012; 12: 356.
89. Morkel M, Riemer P, Blaker H., et al. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget. 2015; 6: 20785-20800.
90. Therkildsen C, Bergmann TK, Hennrichsen-Schnack T., et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014; 53: 852-864.
91. Valtorta E, Misale S, Sartore-Bianchi A., et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer. 2013; 133: 1259-1265.
92. Wong NA, Gonzalez D, Salto-Tellez M., et al. RAS testing of colorectal carcinoma: a guidance document from the association of clinical pathologists molecular pathology and diagnostics group. J Clin Pathol. 2014; 67: 751-757.
93. Ince WL, Jubb AM, Holden SN., et al. Association of k-ras, b-raf and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005; 97: 981-989.
94. Hurwitz HI, Yi J, Ince W., et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of becacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009; 14: 22-28.
95. Loupakis F, Cremolini C, Lonardi S., et al. Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. J Clin Oncol. 2014; 32: abstr 3519.
96. Moscetti L, Nelli F, Fabbri MA., et al. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. Invest New Drugs. 2013; 31: 1035-1043.